A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival rate
6 months
No
Carolyn Sidor, MD, MBA
Study Director
EntreMed
United States: Food and Drug Administration
2076-CL-004
NCT01104675
April 2010
December 2012
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
University of Colorado Cancer Center | Denver, Colorado 80262 |
University of Chicago Medical Center | Chicago, Illinois 60637 |
Indiana University Simon Cancer Center | Indianapolis, Indiana 46202 |
Dana Farber/Partners Cancer Care | Boston, Massachusetts 02115 |